Shenzhen Sungening Biological

Shenzhen Sungening Bio-Tech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases, oncology, and inflammatory conditions. Leveraging its proprietary structure-based drug design (SBDD) and AI-integrated discovery platform, the company has developed a robust pipeline of next-generation treatments, including oral GLP-1 receptor agonists. Sungening Bio aims to address significant unmet medical needs by providing more accessible and effective oral alternatives to injectable biologics. The company's lead candidate, SG001, is currently in clinical development for the treatment of type 2 diabetes and obesity. Backed by prominent life science investors such as Lilly Asia Ventures and Qiming Venture Partners, the company maintains a strong focus on metabolic health and chronic disease management.